Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

FDA approves Versant 440 Molecular System for management of HCV-infected patients

Siemens Healthcare Diagnostics : 19 February, 2008  (New Product)
The US Food and Drug Administration (FDA) has approved Siemens’ Versant 440 Molecular System for use with the Versant HCV RNA 3.0 assay for management of HCV-infected patients undergoing antiviral therapy.
The Versant 440 Molecular System represents the next generation in automated viral load testing, providing laboratories with greater throughput and less hands-on time, maximising productivity to meet the evolving needs of the clinical laboratory.

'We are pleased to offer clinical laboratories leading-edge solutions in molecular diagnostics that support cost-effective and timely screening and treatment of infectious disease,' said Jim Reid-Anderson, chief executive officer, Siemens Healthcare Diagnostics Division. 'The Versant 440 Molecular system provides clinical laboratories and physicians an outstanding tool that enables quantitative monitoring of Hepatitis C and the delivery of personalised treatment that addresses the unique needs of every patient.'

The Versant 440 Molecular System is a branched DNA (bDNA) system designed for flexible walk-away automation. Its single room technology and consolidated footprint allow the system the flexibility to fit anywhere in the clinical laboratory. The Versant 440 System streamlines workflow by integrating bar code data entry, automated reagent processing, signal amplification detection, and a Laboratory Information System interface for downloading patient work lists and results.

'At Siemens, we are intently focused on the development of advanced systems and solutions that will help clinical laboratories enhance their diagnostic capabilities and the efficiency of their operations,' said David Okrongly, senior vice president, Molecular Diagnostics, Siemens Healthcare Diagnostics. 'We are excited by the Versant 440 System's ability to advance molecular testing capability and productivity for our customers through optimised automation, system flexibility, and Assay performance excellence.'

The Versant 440 Molecular System uses bDNA technology that simplifies testing by eliminating nucleic acid extraction and reducing the risk of cross-contamination. With a high level of reproducibility, Versant HCV 3.0 Assay allows viral load changes to be distinguished accurately, enhancing hepatitis C viral load management.

The HCV RNA 3.0 Assay run on the Versant 440 demonstrates precision across the entire reporting range and equivalent detection of all HCV RNA genotypes. CE Marked in September of 2006, the Versant 440 has been successfully launched throughout Europe, Africa, and parts of Asia and the Americas.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo